[A novel Cisplatin delivery system for malignant ascites-bearing mice-a basic experimentation].

The authors used 70% deacetylated chitin and cisplatin (CDDP) to devise a novel anticancer drug delivery system (DDS). We examined in vitro release of the CDDP from the system. The novel system was intraperitoneally( ip) given to malignant ascites-bearing mice, and the survival time of each animal was recorded. The related oncolytic mechanism was immunologically investigated. More than 70-90% of the CDDP was gradually delivered from the system in 24 hours. Nineteen animals among 30 treated with our system survived for longer than 4 weeks, and a recurrence of ascites was nil. A 4- week survival rate of the animals with ip injected conventional CDDP was 5/14. All non-treated animals had massive ascites and died within 4 weeks. Immunologic studies suggested that cytotoxic immunoresponse was induced in the mice treated with the novel system. Our newly devised system warrants for clinical applications in the treatment of malignant ascites.

[The importance of cooperation between nurse and registered dietician toward a QOL improvement of the terminal stage patient--a case of advanced esophageal cancer].

As for the esophageal terminal stage patient with enteral feeding when the patient was hospitalized, an oral nourishment intake support was given with a cooperation of nurse and registered dietician. After that, the patient was transferred to home care and was seceded from PEG. It has been suggested that an early assessment of the problems with the terminal stage patient, ascertainment of home care timing and the team support consisted of multi professionals were all important ingredients.